MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling

AIMS: Heart failure is a major complication in cancer treatment due to the cardiotoxic effects of anticancer drugs, especially from the anthracyclines such as doxorubicin (DXR). DXR enhances oxidative stress and stimulates matrix metalloproteinase-2 (MMP-2) in cardiomyocytes. We investigated whether...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Res
Glavni autori: Chan, Brandon Y H, Roczkowsky, Andrej, Cho, Woo Jung, Poirier, Mathieu, Sergi, Consolato, Keschrumrus, Vic, Churko, Jared M, Granzier, Henk, Schulz, Richard
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7797218/
https://ncbi.nlm.nih.gov/pubmed/31995179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvaa017
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items